logo
Is Fiber the New Protein?

Is Fiber the New Protein?

Yahoo26-06-2025
It was hard to go on social media last year without yet another reminder that you need to eat more protein. Even snack foods now come with 'added protein,' making it clear that this a nutrient you need in your life. But while protein is, and always has been, a crucial part of health, there's another macronutrient of the moment that's stealing the spotlight: fiber.
While protein is important for muscle growth and repair, fiber is a must-have for digestive health, gut microbiome balance and overall well-being—all of which is especially crucial in midlife. Some research even suggests that the ratio of protein to fiber in your diet may have more of an impact on the gut microbiome than fiber, alone, suggesting you don't need to choose sides.
More from Flow Space
6 Expert Recommended Steps to Take Before the FDA Cracks Down on GLP-1 Drugs
Fiber has always been a recommended macronutrient for good health, it's just that the hype around it has changed. Here's what's behind the buzz surrounding fiber, plus why experts are all about it.
Dietary fiber is a type of carbohydrate that comes from plants, according to the U.S. National Library of Medicine. It adds bulk to your diet and makes you feel fuller, faster, explains Keri Gans, RDN, a dietitian and host of The Keri Report podcast.
There are two types of dietary fibers: soluble fiber, which mixes with water to create a gel that slows digestion per the U.S. National Library of Medicine. Insoluble fibers add bulk to help food and waste pass through your gut more easily. Fiber 'plays a key role in overall gut health,' Gans says.
'Soluble fiber may also help to lower cholesterol levels, contributing to heart health,' she adds.
Unfortunately, most Americans don't get enough fiber in their diet; research suggests that just 5% of people consume the recommended amount daily.
It's not entirely clear why fiber seems to be replacing protein as the go-to macronutrient, but there are some theories.
'Many people are becoming more aware of nutrition overall,' says Dr. Mir Ali, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, California.
There's also been a big focus in the healthcare community on the importance of good nutrition, says Dr. Sherry Ross, an OB-GYN and women's health expert at Providence Saint John's Health Center in Santa Monica, California. 'Health and medical experts are focusing on disease prevention through healthy lifestyle habits, starting with dietary choices,' she says. 'Shining a spotlight on fiber should be included on the menu, given its benefits for long-term health.'
Gans says that fiber is 'definitely gaining attention' lately. 'More people are recognizing its role in supporting gut health, promoting regularity and aiding weight management, making it a key player in overall wellness,' she says.
Given all the attention on protein right now—not to mention, research suggesting that a good balance of fiber and protein leads to better gut health—it only seems natural that fiber would get its time in the spotlight, too.
'Both protein and fiber are important for good health,' Ali stresses.
There's a lot to love about fiber.
'Fiber may support weight management, lower the risk of heart disease and promote regularity, all of which are particularly significant during midlife when hormonal changes can affect digestion and overall health,' Gans says. One study published last year in the journal Frontiers in Nutrition also linked a high-fiber diet to bigger weight loss gains compared to people who had less of the macronutrient.
Fiber may even lower the risk of chronic diseases like diabetes, as well as the risk of developing colon cancer, Ali says.
Because fiber comes in plant foods, you're also getting plenty of other health-promoting nutrients when you eat fiber-rich foods, Ali points out.
The current Dietary Guidelines for Americans suggest that people should aim to have 14 grams of fiber per every 1,000 calories of food. So, if you follow a 2,000-calorie diet, it's a good idea to aim for 28 grams of fiber. However, most experts suggest trying to get 25 to 30 grams of fiber per day.
While most Americans fall short on those recommendations, there are plenty of opportunities to get more fiber in your life. The Dietary Guidelines flag these as some of the biggest potential sources:
Ready-to-eat high-fiber cereal, 1/2 cup (14 grams of fiber)
Lima beans, 1 cup (13.2 grams)
Small white beans, 1/2 cup (9.3 grams)
Brussels sprouts, 1 cup (6.4 grams)
Popcorn, 3 cups (5.8 grams)
Broccoli, 1 cup (5.2 grams)
As for that protein-to-fiber ratio, it's still being explored.
'There is no ideal ratio that applies to everyone. Everyone is different,' Ali says. However, he says that the protein-to-fiber ratio is generally two to one. Meaning, you should aim to have double the amount of protein that you take in for fiber.
'If you exercise regularly or are under- or overweight, the amount may vary,' Ross says. If you're concerned about your fiber intake or want to do your best to make sure you're getting in enough protein and fiber, she recommends checking in with a dietitian.
But, again, you don't need to choose sides here.
'Ultimately, choosing meals and snacks that contain both protein and fiber can help with satiety, blood sugar control and sustained energy,' Gans says. Basically, don't sleep on fiber—or protein.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'
Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'

Yahoo

time28 minutes ago

  • Yahoo

Jim Cramer Says He 'Was Discouraged to Get a Mixed Update from Abbott Labs'

Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shed light on. Commenting on the company's recent earnings report results, Cramer said: 'Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the Charitable Trust… I'd say two decades. When Abbott Labs reported this morning, the… results were perfectly solid. Management tightened their full-year earnings guidance rather than raising it while also taking down their organic sales growth forecast and their operating margin outlook. wavebreakmedia/ Abbott (NYSE:ABT) is a healthcare company engaged in the research, development, manufacture, and marketing of a wide range of medical products. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

Yahoo

time28 minutes ago

  • Yahoo

Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition

Eli Lilly and Company (NYSE:LLY) is one of the . Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company (NYSE:LLY) is a research-driven pharmaceutical leader headquartered in Indiana. With a 150-year history, the company carries on the business of discovering, developing, manufacturing, and marketing innovative treatments across diseases like diabetes and in fields like oncology, immunology, and neuroscience. Some of the company's notable products, such as Humalog, Trulicity, Mounjaro, and Zepbound, are marketed in over 125 countries. The company is carrying on multiple studies and its latest updates include the Phase 2b clinical study titled 'A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa' and Phase 3 clinical study titled 'A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids.' Along with these studies, the company has a pipeline with potential drugs capable of generating more than $1 billion in annual revenue. Amid these studies, the company has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion. With this acquisition, Eli Lilly and Company (NYSE:LLY) aims to strengthen its positions in gene editing for cardiovascular conditions. With a beta of 0.44 signaling the company's resistance to market conditions, Eli Lilly and Company (NYSE:LLY) has a high anticipated 5-year EPS growth of 41.87%, making the stock a strong contender in our list. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None.

Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care

Yahoo

time28 minutes ago

  • Yahoo

Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care

Milestone Highlights Rapid Hospital Adoption and Clinical Demand for Arrhythmia Insights that Improve Outcomes and Reduce Procedure Time SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States. "vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation." As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA. "This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care." The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact. To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit and connect with us on LinkedIn and X. About Vektor Medical Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit View source version on Contacts Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store